On July 27, 2022 Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, reported that its management team will participate in a virtual fireside chat at the upcoming 13th Annual Wedbush PacGrow Healthcare Conference (Press release, Arcus Biosciences, JUL 27, 2022, View Source [SID1234617030]). The fireside chat will take place on Wednesday, August 10th, 2022 at 12:00 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available by visiting the "Investors & Media" section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event.

On July 27, 2022 MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, reported the pricing of its initial public offering of 2,000,000 shares of the Company’s common stock at a public offering price of $5.00 per share for aggregate gross proceeds of $10,000,000 prior to deducting underwriting discounts, commissions, and other offering expenses (Press release, MAIA Biotechnology, JUL 27, 2022, View Source [SID1234617029]). In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 shares of common stock at the public offering price, less discounts and commissions, to cover over-allotments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The shares of common stock are expected to begin trading on the NYSE American under the ticker symbol "MAIA" on July 28, 2022. The offering is expected to close on August 1, 2022, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the initial public offering to fund the first part of the Phase 2 trials of the Company’s product candidate THIO, pre-clinical development of second-generation of telomere targeting compounds and other research and development activities, as well as for working capital and other general corporate purposes.

ThinkEquity is acting as sole book-running manager for the offering.

The registration statement on Form S-1 (file No. 333-264225) relating to the shares being sold in this offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") and became effective on July 27, 2022. A final prospectus related to the proposed offering will be filed and made available on the SEC’s website at View Source The offering is being made only by means of a prospectus. Electronic copies of the final prospectus may be obtained, when available, from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004, by telephone at (877) 436-3673 and by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On July 27, 2022 Novocure reported the recipients of the 4th Annual AACR (Free AACR Whitepaper)-Novocure Grants for Tumor Treating Fields Research Program (Press release, NovoCure, JUL 27, 2022, View Source [SID1234617028]). The AACR (Free AACR Whitepaper)-Novocure Grants for Tumor Treating Fields Research Program represents a joint effort between Novocure and the American Association for Cancer Research (AACR) (Free AACR Whitepaper) to promote and support innovative research on Tumor Treating Fields (TTFields) . The AACR (Free AACR Whitepaper) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Such collaborations help to deepen the understanding of TTFields’ mechanism of action and to identify its optimal use. Extensive preclinical and clinical evidence provides the foundation upon which Novocure executes its strategy to advance TTFields through additional clinical research studies across multiple solid tumor types.

Professor Wafik El-Deiry, M.D., Ph.D., FACP, Director of the Legorreta Cancer Center at Brown University and Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, is one of the grant recipients. His hypothesis is based on a prediction that therapeutic agents that trigger cell stress pathways in different ways may cooperate to achieve a greater therapeutic effect in various cancers.

Over the past year, Dr. El-Deiry, an expert in cancer biology, has become interested in TTFields and their potential to affect the integrated stress response, a signaling network within cells that is related to their survival. His research group will combine TTFields with other therapies, including the oral drug ONC201, and study how the combinations affect the integrated stress response in various cancer types.

"I’m a practicing clinical oncologist. I see patients every week," said Dr. El-Deiry. "I’m well aware of the genes that contribute to tumor progression, drug resistance, and failure of the immune response, and clearly we need to do better. There’s a certain skillset that I think we have, to be able to design and propose rational combinations in different tumor types to achieve tumor regression with limited toxicity. I look forward to researching how TTFields, when used in combination with other therapies, affects many different solid tumor types."

Recipients of the AACR (Free AACR Whitepaper)-Novocure Tumor Treating Fields Research Grants will receive a total of $250,000 over two years.

"Congratulations to the recipients of the AACR (Free AACR Whitepaper)-Novocure Tumor Treating Fields Research Grants," said Uri Weinberg, Novocure’s Chief Science Officer. "We are honored to collaborate with the AACR (Free AACR Whitepaper) to support research to unlock new insights about TTFields that could lead to new treatment strategies for aggressive cancers. We wish the award recipients success as they pursue this important research."

2022 AACR (Free AACR Whitepaper)-Novocure Tumor Treating Fields Research Grants

Wafik El-Deiry, M.D., Ph.D., FACP; Brown University; Integrated Stress Response induction by TTFields + ONC201 in cancer treatment
Matthew R. Sarkisian, Ph.D.; University of Florida; Improving TTFields Efficacy by Altering Ciliogenesis
Stuart Smith, Ph.D.; University of Nottingham; Combining Tumor Treating Fields with Ion Channel Blockade
ABOUT TUMOR TREATING FIELDS

Tumor Treating Fields, or TTFields, are electric fields that disrupt cancer cell division. Fundamental scientific research extends across more than two decades and, in all preclinical research to date, TTFields have demonstrated a consistent anti-mitotic effect. TTFields therapy is intended principally for use together with other standard-of-care cancer treatments. There is a growing body of evidence that supports TTFields’ broad applicability with certain other cancer therapies, including radiation therapy, certain chemotherapies and certain immunotherapies. In clinical research and commercial experience to date, TTFields therapy has exhibited no systemic toxicity, with mild to moderate skin irritation being the most common side effect. The TTFields global development program includes a network of preclinical collaborators and a broad range of clinical trials across all phases, including four phase 3 pivotal trials in a variety of tumor types. To date, more than 24,000 patients have been treated with TTFields therapy.

On July 27, 2022 The Parker Institute for Cancer Immunotherapy (PICI) is helping to forge a future without cancer, reported by investing in top talent to train and empower the research leaders of tomorrow (Press release, Parker Institute for Cancer Immunotherapy, JUL 27, 2022, View Source [SID1234617027]). This year, PICI recognized its largest Early Career Researcher class yet, nine exceptional graduate and postdoctoral researchers from leading academic institutions. They will share a total of up to $4.5 million in fellowship and scholarship awards.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Marking the Early Career Researcher program’s sixth anniversary, previous awardees recently presented their work to the PICI Network of world-renowned innovators in cancer immunotherapy research at the organization’s biannual scientific retreat.

As a part of this ongoing program, PICI is furthering its commitment to addressing disparities in the field of cancer research through diversity, equity, inclusion and belonging initiatives. Those include the creation of its Representation In SciencE (RISE) Scholar program, which awards a Black, Indigenous or Person of Color (BIPOC) graduate or rising postdoctoral student who has an outstanding scientific background and conducts research at a PICI Network institution.

"The 2022 awardees, like those who have come before them, are among the best and brightest minds anywhere," said John Connolly, Ph.D., chief scientific officer at PICI. "We are proud to support these researchers, who are dedicated to innovating our approach to cancer to improve patient outcomes."

This year, PICI also is proud to partner with the V Foundation for Cancer Research to fund four of the nine class of 2022 awardees. Known as Parker Bridge Fellows, the four recipients are senior postdoctoral investigators working to answer the most critical questions in cancer immunotherapy as they transition into faculty positions following mentorship by PICI’s network of leaders.

The 2022 Parker Bridge Fellows are:

Katie Campbell, Ph.D., University of California, Los Angeles (UCLA)
Kenneth Hu, Ph.D., University of California, San Francisco (UCSF)
Derek Oldridge, M.D., Ph.D., University of Pennsylvania (Penn)
Bingfei Yu, Ph.D., Stanford Medicine
"Our mission is to support cutting-edge cancer research, so as many patients as possible can benefit from the extraordinary breakthroughs that researchers are making today," said Susanna Greer, Ph.D., chief scientific officer at the V Foundation. "PICI helps us further the V Foundation’s mission to fund accomplished young researchers bringing new techniques to combat cancer that warrant further exploration. We’re thrilled to support this work and to get to know these rising stars."

This year, an anonymous donor has committed substantial funding to create the Parker RISE Scholar award. The inaugural RISE Scholar is Gabriel Abril Rodriguez, Ph.D., a postdoctoral researcher at UCLA.

"The scholarship is a validation of my project idea, which is a very ambitious, high-impact project," said Abril Rodriguez, who is developing new tools to study T-cell biology. "As part of the PICI Network, I will interact and share my ideas with some of the brightest minds in the field. Learning from them will help me push this project forward."

The other award categories are:

Parker Senior Fellow – a senior researcher who recently has earned an M.D. or Ph.D. degree and is ready to establish a laboratory or independent program in cancer immunotherapy. The 2022 Parker Senior Fellow is Ya-Ting (Emma) Wang, Ph.D., of Memorial Sloan Kettering Cancer Center (MSK).
Parker Scholars – graduate students and researchers focused on high-impact projects who are entering their first postdoctoral appointments. The 2022 Parker Scholars are Inaki Etxeberria, Ph.D., of MSK, Louai Labanieh, Ph.D., of Stanford and Darwin Ye, a doctoral candidate at Penn.
"My project involves learning how cells become resistant to immunotherapy so we can design more effective clinical trials, and this is something that requires an interdisciplinary approach," Ye said. "The PICI Network lets me explore that approach with leading cancer researchers in the field."

With this year’s class, PICI has recognized 37 Early Career Researchers since 2016, awarding over $19 million in total funding and welcoming them into the PICI Network. They are working to advance cancer research on cell and gene therapies, CAR T cells, immune checkpoint blockade therapy and other critical scientific projects.

Awardees pursue bold research through support from PICI’s world-class network of immunotherapy experts and research institutions, as well as individual mentorship by PICI members and researchers from affiliated institutions. They also are given access to leading-edge technology, informatics and clinical data needed for their research.

"This fellowship allows me to collaborate and communicate with experts from very different fields, including cancer biologists, computational biologists and clinical scientists," said Yu, a Stanford immunologist and postdoctoral scientist who is doing research on the targeting mechanisms that T cells and other immune cells use to kill cancer. "Being able to learn from these leaders while also operating my own lab is an incredible opportunity."

On July 27, 2022 City of Hope, one of the largest cancer research and treatment organizations in the United States, reported that opens its visionary comprehensive cancer center in Orange County, California, creating a national model for delivering breakthrough research and pioneering treatments (Press release, City of Hope, JUL 27, 2022, View Source [SID1234617026]). The academic cancer center ushers in a new era of hope for people with cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Here, a team of some of the world’s most acclaimed physician-scientists — with expertise in lung, breast, gastrointestinal, gynecological, genitourinary, blood cancers and more — leads next-level cancer treatment and research.

City of Hope Orange County Lennar Foundation Cancer Center was made possible by a transformational $50 million gift from Lennar Foundation, the charitable arm of homebuilder Lennar Corporation. In Orange County alone, City of Hope has more than 15,000 philanthropic supporters who fuel its mission to end cancer.

A Cancer Crisis in Orange County and Across the Nation

City of Hope officials cite several reasons for an expanded presence in the region.

Nearly 20% of residents with cancer have left the area for advanced care, with many heading to City of Hope’s main campus in Duarte, California — an up to two-hour commute each way. In addition, despite its reputation for healthy living, Orange County is not immune from the 1 in 3 national statistic for cancer incidence.

In fact, the cancer incidence rate in the county is projected to increase by 18% over the next decade. Cancer risk increases with age and Orange County has a higher percentage of seniors than the U.S. average.

City of Hope, one of only 52 National Cancer Institute-designated comprehensive cancer centers in the country, is answering the call to extend its personalized care, outstanding research and lifesaving treatments closer to home for the county’s 3.2 million residents. City of Hope was recognized as the seventh "Best Hospital" for cancer in the nation, according to U.S. News & World Report’s 2022-23 Best Hospitals: Specialty Ranking.

Distinguishing clinical services at City of Hope Orange County Lennar Foundation Cancer Center will include:

Acclaimed cancer expertise: Access to City of Hope’s 575 physicians and more than 1,000 researchers and scientists who only focus on cancer.
Lifesaving clinical trials: Access to nearly 1,000 innovative Phase 1-3 clinical trials being conducted at City of Hope each year — more cancer-focused clinical trials than anywhere in the area — to provide patients with promising new treatments long before they become the standard of care.
Breakthrough treatments: Targeted immunotherapies, including CAR T cell therapy, as well as bone marrow transplants, robotic minimally invasive surgeries and MRI-guided radiation oncology. These innovations have demonstrated improved outcomes and a better quality of life for patients in treatment.
Leading-edge technology: The latest and most comprehensive suite of market-leading radiology, interventional radiology and radiation oncology equipment, providing a powerful combination of high tech and high touch.
Integrative medicine: A trailblazing integrative medicine program combining the best of Western medicine and evidence-based complementary therapies, such as acupuncture, massage and meditation.
Cancer prevention: Programs that identify people and families with elevated cancer risk utilizing genetic risk assessments, biomarker panels and environmental surveys to help manage that risk.
Early detection: Novel blood testing and imaging techniques that find cancer early, when it is still easily curable. Patients will be among the first in the nation to have access to City of Hope’s new Center for Cancer Prevention and Early Detection.
Precision medicine: Best-in-class genomic testing to profile a patient’s tumor and determine the treatment that will be most effective for their cancer.
Screening and diagnostic services: A suite of state-of-the-art imaging equipment and procedural suites, giving patients convenient access to mammography, colonoscopy, robotic bronchoscopy and other lifesaving services.
A clinical research unit: The epicenter for clinical investigational research that speeds the development of new drugs and interventions to the bedside, allowing patients to receive the latest treatments in cancer care.
Surgical oncology: An outpatient surgery department that offers advanced perioperative care, an endoscopy suite and operating rooms with robotic-assisted surgical capabilities.
Supportive care: City of Hope is a national leader in evidence-based supportive care. The Sheri & Les Biller Patient and Family Resource Center at the comprehensive cancer center in Irvine will facilitate easy access to a wide range of programs, including care navigation, survivorship programs, psychological and spiritual counseling, pain management and more.
Built For and With the Community

City of Hope Orange County Lennar Foundation Cancer Center was designed with input from more than 500 patients, their families and community members. Every feature of the cancer center — from the design of its gathering spaces to its lighting, its wall color, even its artwork selection — was intentionally chosen to promote healing and comfort and ensure patients and their families have the best care experience. Every employee is committed to delivering compassionate care, continuing the City of Hope legacy of taking patients’ hands and never letting go.

Features include:

67 spacious exam and treatment rooms.
15 consultation rooms equipped with the latest technology, allowing patients and family members to meet comfortably with their care team.
An infusion center designed around patient preferences with 43 infusion bays and 10 private infusion treatment rooms. The infusion bays feature repositionable furnishings, flexible privacy options, and panoramic views of the Saddleback mountains.
Hope Boutique, a full-service salon and specialty shopping experience with oncology-trained cosmetologists who help patients with customized cosmetology services, breast prostheses and more.
A retail and specialty pharmacy that dispenses traditional, specialty, and over-the-counter medications, alleviating the travel burden on patients for their medication needs. In addition, a compounding pharmacy provides a full evaluation of patients’ needs and prepares personalized chemotherapeutic and non-chemotherapeutic medications. Specialty-trained clinical pharmacists assist patients with medication management.
A full range of state-of-the-art laboratory services in one location, making it convenient for patients to get routine blood draws.
Feng Shui design, art galleries, a healing garden, dedicated space for family members to gather or work, and programs to care for the whole patient — mind, body, and spirit.
City of Hope Orange County’s cancer care network currently includes four regional clinics — two in Newport Beach, one in Huntington Beach and one in Irvine. The cancer center, the regional clinics and the planned hospital will create Orange County’s largest network dedicated exclusively to cancer treatment and cures.

Supporting quotes

Robert Stone, president, CEO, and Helen and Morgan Chu Chief Executive Officer Distinguished Chair, City of Hope
"City of Hope’s vision is to make leading-edge research, treatment and care accessible to more patients, families and communities across the country. Our new Orange County campus does just that, embedding an academic cancer center in the heart of a community to deliver cancer breakthroughs and innovation for generations of patients in need of our advanced care. Thank you to the teams, partners, and philanthropists who brought us to this historic day."

Annette M. Walker, president, City of Hope Orange County
"With the opening of City of Hope Orange County Lennar Foundation Cancer Center, we are delivering on our promise to the people of Orange County and changing cancer care for our family, friends and neighbors. Four years ago, we pledged to bring the most advanced cancer care to Orange County, home to 3.2 million people. As we open our cancer center’s doors, our highly committed teams join the community in celebrating the delivery of tomorrow’s lifesaving treatments to those who need them today. Hope is truly here in Orange County."

Edward S. Kim, M.D., M.B.A., physician-in-chief, City of Hope Orange County, and vice physician-in-chief, City of Hope National Medical Center
"This extraordinary cadre of preeminent cancer physician-scientists changes the Orange County landscape. Our physician roster comprises many of the best minds in the world for preventing, treating, and curing cancer. With their highly specialized expertise, distinguished history of research breakthroughs and compassionate approach, this team will transform our ability to address cancer for generations."

Marshall H. Ames, chairman, Lennar Foundation
"Giving back to the communities in which we build and developing healthier communities are core values at Lennar. The Lennar Foundation could not be prouder to have supported this new cancer center. It is gratifying to know that our gift will make a positive impact by expanding access to care, advancing research and supporting the incredible science that will one day eliminate cancer. We hope others in the philanthropic community will see the results of our efforts and join us in supporting City of Hope."

Farrah N. Khan, mayor of Irvine
"City of Hope Orange County is well-matched for Irvine, heightening our city’s reputation for pioneering innovation. This is an outstanding health care resource for the community and brings great promise to many. The center has already attracted exceptional health care professionals eager to save lives and offer our friends and neighbors a tremendous source of hope."

Leslie Bruce Amin, grateful patient
"I’ve been waiting for this day ever since City of Hope announced its plans for an Orange County campus. Whenever I connect with people navigating a cancer diagnosis, my first piece of advice is to always find a cancer-specific research center for the most advanced care. Now, right here in our community, people with cancer have the highly specialized and compassionate care they need — all in one place."

For more information or to become a volunteer or philanthropic partner of City of Hope Orange County, go to CityofHope.org/OC